isobutylmethylxanthine
IBMX (3-isobutyl-1-methylxanthine), like other methylxanthine derivatives, is both a: competitive non-selective phosphodiesterase inhibitor which raises intracellular cAMP, activates PKA, inhibits TNFα and leukotriene synthesis, and reduces inflammation and innate immunity, and nonselective adenosine receptor antagonist.
Chemical data
- Formula
- C10H14N4O2
- Molecular weight
- 222.24 g/mol
- IUPAC name
- 1-methyl-3-(2-methylpropyl)-7H-purine-2,6-dione
via PubChem
Research
1,522 papers- Nypa fruticans Wurmb inhibits melanogenesis in isobutylmethylxanthine‑treated melanoma via the PI3K/AKT/mTOR/CREB and MAPK signaling pathways.Experimental and therapeutic medicine · 2022
- Isobutylmethylxanthine and other classical cyclic nucleotide phosphodiesterase inhibitors affect cAMP-dependent protein kinase activity.Cellular signalling · 1993
- Effects of cholera toxin and isobutylmethylxanthine on growth of human fibroblasts.The American journal of physiology · 1986
- Effect of forskolin and isobutylmethylxanthine on delta-opioid receptor activity in neuroblastoma x glioma NG108-15 cells.The Journal of pharmacology and experimental therapeutics · 1993
Article
1 sectionsContents
- References
IBMX (3-isobutyl-1-methylxanthine), like other methylxanthine derivatives, is both a: competitive non-selective phosphodiesterase inhibitor which raises intracellular cAMP, activates PKA, inhibits TNFα and leukotriene synthesis, and reduces inflammation and innate immunity, and nonselective adenosine receptor antagonist.
As a phosphodiesterase inhibitor, IBMX has IC50 = 2–50 μM and does not inhibit PDE8 or PDE9.